Word of the biotech's pending acquisition pushed its stock to a record high.
News & Analysis: Forty Seven
The immuno-oncology buyout is set to close this quarter.
Take advantage of a declining stock price for this soon-to-be-acquired company.
The cancer treatment specialist found a buyer for its business.
The deal will enable Gilead to scoop up promising blood cancer drug magrolimab.
Gilead Sciences and Forty Seven are reportedly tying the knot through a $4.9 billion buyout agreement. Shares of Trillium Therapeutics, a fellow CD47 drugmaker, are also jumping on this news.
Forty Seven shares soared on the rumor, but Gilead's stock price fell.
Gilead is reportedly courting the cancer specialist Forty Seven about a possible buyout.
Positive data from a recent study on its lead compound signifies a turning point for the company and could provide further value for investors.
These two small-cap biopharmas have promising early-stage drug candidates that could take them far if all goes according to plan.